Patent · US Expired

2,6-Substituted chroman derivatives useful as beta-3 adrenoreceptor agonists

US6660752B2 · kind B2 · utility

12Cited by

14References

30Claims

0Family size

Assignee

Bayer Pharmaceuticals Corporation · US

Inventors

Stephen O'Connor · Wilmette, US
Gaetan Ladouceur · Guilford, US
William Bullock · Easton, US
Ann-Marie Campbell · Monroe, US
Miao Dai · Shanghai, CN
Robert Dally · Indianapolis, US
Jacques Dumas · Neuilly-Plaisance, FR
Holia Hatoum-Mokdad · Hamden, US
Uday Khire · Hamden, US
Wendy Lee · Hamden, US
Qingjie Liu · Newtown, US
Derek Lowe · Scotch Plains, US
Steven R. Magnuson · South San Francisco, US
Ning Qi · Somerville, US
Tatiana Shelekhin · Ridgefield, US
Quanrong Shen · Indianapolis, US
Roger Smith · Madison, US
Ming Wang · Montgomery, US

Key dates

Filing date	Apr 22, 2002
Grant date	Dec 9, 2003
Priority date	—
Expiry date	Apr 22, 2022

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D417/14
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

This invention relates to novel 2,6-substituted chroman derivatives which are useful in the treatment of beta-3 adrenoreceptor-mediated conditions.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.